NOVARTIS COSENTYX SHOWS SUPERIOR IMPROVEMENTS IN PSORIASIS PATIENTS’ QUALITY OF LIFE VERSUS JOHNSON & JOHNSON UNIT JANSSEN’S IL-23 STELARA
* NOVARTIS SAYS COSENTYX SHOWS SUPERIOR IMPROVEMENTS IN PSORIASIS PATIENTS’ QUALITY OF LIFE VERSUS JANSSEN’S IL-23 STELARA
* IN ADDITION, NEW PROSE STUDY DATA PRESENTED AS A LATE-BREAKER SUPPORTING BENEFIT OF COSENTYX TO IMPROVE PATIENT QOL
* COSENTYX CONTINUES TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE
* J&J PREVIOUSLY PUBLISHED STUDY SHOWING STELARA BEAT COSENTYX
